A Whitney Brown1, Chelsea P Fischer1, Oksana A Shlobin1, Russell G Buhr2, Shahzad Ahmad1, Nargues A Weir1, Steven D Nathan3. 1. Advanced Lung Disease and Transplant Program; University of California at Los Angeles, Los Angeles, CA. 2. Department of Medicine, Inova Fairfax Hospital, Falls Church, VA; and the Department of Medicine; Department of Medicine; University of California at Los Angeles, Los Angeles, CA. 3. Advanced Lung Disease and Transplant Program; University of California at Los Angeles, Los Angeles, CA.. Electronic address: steven.nathan@inova.org.
Abstract
OBJECTIVE: The outcomes of patients with idiopathic pulmonary fibrosis (IPF) who undergo hospitalization have not been well characterized. We sought to determine the frequency of all-cause and respiratory-related hospitalizations and to evaluate their impact on the subsequent course and survival of patients with IPF. METHODS: The records of patients with IPF evaluated at a tertiary center were examined for the cause and duration of hospitalization. Data on subsequent patient outcomes were collated. RESULTS: The IPF cohort consisted of 592 patients, 25.3% of whom were hospitalized subsequent to their IPF diagnosis. A respiratory-related cause accounted for 77.3% of these hospitalizations. The median transplant-free survival for all patients was 23.3 months (interquartile range [IQR], 7.6-63.6 months) from the time of consultation. Transplant-free survival after hospital admission was much lower for patients with a respiratory hospitalization compared with those with a nonrespiratory hospitalization (median survival, 2.8 months [IQR, 0.63-16.2 months] vs 27.7 months [IQR, 7.4-59.6 months]; P = .0004). Multivariate analyses demonstrated that both all-cause and respiratory-related hospitalizations were strongly associated with mortality after adjusting for baseline demographics. Among patients with a respiratory hospitalization, 22.4% died while in the hospital, whereas 16.4% eventually went on to lung transplantation. CONCLUSIONS: Hospitalizations are common events in patients with IPF. Most hospitalizations are respiratory-related and are associated with high in-hospital mortality and limited survival beyond discharge. Both all-cause and respiratory hospitalizations are associated with mortality, and therefore, either could be used as an end point in IPF clinical trials.
OBJECTIVE: The outcomes of patients with idiopathic pulmonary fibrosis (IPF) who undergo hospitalization have not been well characterized. We sought to determine the frequency of all-cause and respiratory-related hospitalizations and to evaluate their impact on the subsequent course and survival of patients with IPF. METHODS: The records of patients with IPF evaluated at a tertiary center were examined for the cause and duration of hospitalization. Data on subsequent patient outcomes were collated. RESULTS: The IPF cohort consisted of 592 patients, 25.3% of whom were hospitalized subsequent to their IPF diagnosis. A respiratory-related cause accounted for 77.3% of these hospitalizations. The median transplant-free survival for all patients was 23.3 months (interquartile range [IQR], 7.6-63.6 months) from the time of consultation. Transplant-free survival after hospital admission was much lower for patients with a respiratory hospitalization compared with those with a nonrespiratory hospitalization (median survival, 2.8 months [IQR, 0.63-16.2 months] vs 27.7 months [IQR, 7.4-59.6 months]; P = .0004). Multivariate analyses demonstrated that both all-cause and respiratory-related hospitalizations were strongly associated with mortality after adjusting for baseline demographics. Among patients with a respiratory hospitalization, 22.4% died while in the hospital, whereas 16.4% eventually went on to lung transplantation. CONCLUSIONS: Hospitalizations are common events in patients with IPF. Most hospitalizations are respiratory-related and are associated with high in-hospital mortality and limited survival beyond discharge. Both all-cause and respiratory hospitalizations are associated with mortality, and therefore, either could be used as an end point in IPF clinical trials.
Authors: Michael T Durheim; Harold R Collard; Rhonda S Roberts; Kevin K Brown; Kevin R Flaherty; Talmadge E King; Scott M Palmer; Ganesh Raghu; Laurie D Snyder; Kevin J Anstrom; Fernando J Martinez Journal: Lancet Respir Med Date: 2015-04-15 Impact factor: 30.700
Authors: Brett Ley; Jeffrey Swigris; Bann-Mo Day; John L Stauffer; Karina Raimundo; Willis Chou; Harold R Collard Journal: Am J Respir Crit Care Med Date: 2017-09-15 Impact factor: 21.405
Authors: Brett Ley; Williamson Z Bradford; Eric Vittinghoff; Derek Weycker; Roland M du Bois; Harold R Collard Journal: Am J Respir Crit Care Med Date: 2016-09-15 Impact factor: 21.405
Authors: Bryan T Kelly; Viengneesee Thao; Timothy M Dempsey; Lindsey R Sangaralingham; Stephanie R Payne; Taylor T Teague; Teng Moua; Nilay D Shah; Andrew H Limper Journal: BMC Pulm Med Date: 2021-07-17 Impact factor: 3.317